Dosage frequency for suppression of platelet function by low dose aspirin therapy.
A study of platelet aggregation and MDA production after an oral dose of 300 mg aspirin indicated that partial recovery of platelet function occurred when approximately one third of the circulating platelets had been replaced by new (uninhibited) platelets. In vitro studies on mixtures of normal and aspirin inhibited platelets indicated partial restoration of platelet aggregation and thromboxane B2 production with as little as 10% of normal platelets in some subjects. Restoration of full function required a higher proportion of normal platelets. There was considerable variation between subjects. These data suggest that complete suppression of platelet functions in all normal subjects requires daily administration of the drug.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D003094:Collagen / Q000494:pharmacology; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D008315:Malondialdehyde / Q000096:biosynthesis; D010974:Platelet Aggregation / Q000187:drug effects*; D010979:Platelet Function Tests; D013927:Thrombosis / Q000188:drug therapy; D013929:Thromboxane B2 / Q000096:biosynthesis
D008315:Malondialdehyde; D013929:Thromboxane B2; D000244:Adenosine Diphosphate; D003094:Collagen; D001241:Aspirin; D004837:Epinephrine